Wang Wenjuan, Lv Junxia, Chen Nan, Lou Bin, Mao Weilin, Wang Peipei, Chen Yu
Department of Laboratory Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China; Key Laboratory of Clinical In Vitro Diagnostic Techniques of Zhejiang Province, Hangzhou, Zhejiang 310003, China.
Department of Laboratory Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China; Key Laboratory of Clinical In Vitro Diagnostic Techniques of Zhejiang Province, Hangzhou, Zhejiang 310003, China.
Clin Biochem. 2018 Nov;61:7-11. doi: 10.1016/j.clinbiochem.2018.09.002. Epub 2018 Sep 6.
Correct staging of hepatocellular carcinoma (HCC) could help physicians to precisely select treatments for patients, such as surgery, chemotherapy, or their combination. The objective of this study was to explore potential metabolic markers for staging of hepatocellular carcinoma.
By liquid chromatography with mass spectrometry (LC-MS), the serum metabolic profiles of 60 pathologically confirmed hepatocellular carcinoma (HCC) patients were analyzed using the TNM staging system and Chinese staging system.
The serum levels of dihydrocortisol, lysophosphatidylcholine (LPC-18:0), lysophosphatidylethanolamine (LPE-16:0), taurine, uric acid, adipic acid, tetracosatetraenoic acid, and L-octanoylcarnitine differed significantly between staging I and non-stage I HCCs (p < 0.05) based on the HCC TNM staging system, and compared to stage I sera, non-stage I sera contained higher levels of dihydrocortisol, adipic acid, tetracosatetraenoic acid, and L-octanoylcarnitine. There are significant differences were observed in serum levels of LPC (22:6), alpha-linolenylcarnitine, estrone, LPE (16:0), LPE (18:2), and taurine between stage I and stage II HCCs (p < 0.05) based on the Chinese HCC staging system, and compared to stage I sera, stage II sera had a higher level of LPC (22:6).
These dysregulated metabolites in sera of HCC patients potentially could be used as biomarkers for the clinical staging of HCC.
肝细胞癌（HCC）的准确分期有助于医生为患者精确选择治疗方法，如手术、化疗或联合治疗。本研究的目的是探索肝细胞癌分期的潜在代谢标志物。
采用液相色谱 - 质谱联用（LC-MS）技术，使用TNM分期系统和中国分期系统分析60例经病理确诊的肝细胞癌（HCC）患者的血清代谢谱。
基于HCC的TNM分期系统，I期与非I期HCC患者血清中双氢皮质醇、溶血磷脂酰胆碱（LPC-18:0）、溶血磷脂酰乙醇胺（LPE-16:0）、牛磺酸、尿酸、己二酸、二十四碳四烯酸和L-辛酰肉碱水平存在显著差异（p<0.05），与I期血清相比，非I期血清中双氢皮质醇、己二酸、二十四碳四烯酸和L-辛酰肉碱水平更高。基于中国HCC分期系统，I期与II期HCC患者血清中LPC（22:6）、α-亚麻酸肉碱、雌酮、LPE（16:0）、LPE（十八碳二烯酸）和牛磺酸水平存在显著差异（p<0.05），与I期血清相比，II期血清中LPC（22:6）水平更高。
HCC患者血清中这些失调的代谢物有可能用作HCC临床分期的生物标志物。
